MARKET

TYRA

TYRA

Tyra Biosciences, Inc.
NASDAQ
21.75
-4.98
-18.63%
Opening 12:47 09/09 EDT
OPEN
18.94
PREV CLOSE
26.73
HIGH
21.90
LOW
18.76
VOLUME
3.91M
TURNOVER
--
52 WEEK HIGH
40.65
52 WEEK LOW
11.70
MARKET CAP
1.30B
P/E (TTM)
-9.0894
1D
5D
1M
3M
1Y
5Y
1D
Midday Fly By: Analog acquires Alif, Independence Realty merges with Centerspace
TipRanks · 3h ago
Analysts Are Bullish on These Healthcare Stocks: Amgen (AMGN), Tyra Bioscience (TYRA)
TipRanks · 4h ago
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
Barron‘s · 4h ago
Tyra Biosciences Shares Sink After Bladder-Cancer Treatment Causes Adverse Events in Some Patients During Clinical Trial
Dow Jones · 4h ago
Morning Movers: Oddity surges following quarterly results
TipRanks · 6h ago
Tyra data ‘lukewarm, but not program terminating,’ says Jones
TipRanks · 6h ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 7h ago
Tyra drops after mid-stage trial data for lead asset in bladder cancer
Seeking Alpha · 7h ago
More
About TYRA
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help it design and predict which candidates may demonstrate highest potency, selectivity and tolerability in clinic. Its expertise in FGFR biology has created a pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. It is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in SURF431 study (advanced hepatocellular carcinoma), and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in SURF201 study (metastatic intrahepatic cholangiocarcinoma).

Webull offers Tyra Biosciences Inc stock information, including NASDAQ: TYRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TYRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TYRA stock methods without spending real money on the virtual paper trading platform.